Aquestive Therapeutics, Inc. (AQST) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Abeona Therapeutics, Inc.

Aquestive Therapeutics, Inc.

Pyxis Oncology, Inc.

Milestone Pharmaceuticals, Inc.

MediWound Ltd.

Relmada Therapeutics, Inc.

Achieve Life Sciences, Inc.

DiaMedica Therapeutics, Inc.

MediciNova, Inc.

Atossa Therapeutics, Inc.

GlycoMimetics, Inc.

Why is Aquestive Therapeutics, Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of -0.57% and Operating profit at -19.25% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -2.40

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 38.53%, its profits have fallen by -89.8%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Aquestive Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Aquestive Therapeutics, Inc.

38.53%

0.82

86.24%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-0.57%

EBIT Growth (5y)

-19.25%

EBIT to Interest (avg)

-2.40

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.84

Sales to Capital Employed (avg)

4.59

Tax Ratio

0.03%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

75.38%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-14.57

EV to EBIT

-6.99

EV to EBITDA

-7.04

EV to Capital Employed

-17.91

EV to Sales

11.15

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company

NET SALES(Q)

Highest at USD 14.45 MM

RAW MATERIAL COST(Y)

Fallen by -31.29% (YoY

CASH AND EQV(HY)

Highest at USD 231.9 MM

OPERATING PROFIT(Q)

Highest at USD -4.08 MM

OPERATING PROFIT MARGIN(Q)

Highest at -28.28 %

PRE-TAX PROFIT(Q)

Highest at USD -8.06 MM

NET PROFIT(Q)

Highest at USD -8.06 MM

EPS(Q)

Highest at USD -0.07

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for Aquestive Therapeutics, Inc.

Net Sales

Highest at USD 14.45 MM and Grown

In each period in the last five periods

MOJO Watch

Near term sales trend is very positive

Net Sales (USD MM)

Net Sales

At USD 14.45 MM has Grown at 65.67%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (USD MM)

Operating Profit

Highest at USD -4.08 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at -28.28 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at USD -8.06 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Pre-Tax Profit

At USD -8.06 MM has Grown at 64.86%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -8.06 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Net Profit

At USD -8.06 MM has Grown at 64.86%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -0.07

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Cash and Eqv

Highest at USD 231.9 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -31.29% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales